

## HEMOSTATIC AGENTS MARKET ANALYSIS

Cholliiev Meret, Karpenko L. A.

National University of Pharmacy, Kharkiv, Ukraine

socpharm@nuph.edu.ua

**Introduction.** Injuries with bleeding ranks first among various injuries in case of accidents, road traffic accidents. injury problem is particularly relevant to disaster medicine.

Injuries are a leading cause of death of people during man-made, natural (earthquakes, hurricanes, landslides), social, military emergencies. Therefore, the task of market research of hemostatic medicines remains relevant.

**Aim.** Market analysis of hemostatic agents in Ukraine.

**Materials and methods.** The research objects were the data of the State Register of Medicinal Products and ATC code. The methods of information retrieval and marketing analysis were used.

**Results and discussion.** According to the ATC classification system hemostatic medicines are a group B - «Blood and blood forming organs» and form group B02 – «Antihemorrhagics» including subgroups B02A – «Antifibrinolytics» and B02B – «Vitamin K and other hemostatics». Subgroups B02A shows 2 pharmaco-therapeutic groups (B02A A – «Amino acids» and B02A B – «Proteinase inhibitors») and 3 positions of pharmaceutical products. Subgroup B02B represented by 4 pharmaco-therapeutic groups and by 13 positions of pharmaceuticals.

According to the State register of medicines, as of January 1, 2016 in Ukraine 49 commercial drugs names of group B were registered (re-registered), which are represented by different dosage forms in accordance with their dosages, among them 73% are solutions for injection (or a lyophilized powder for reconstitution solution for injection), 12.5% - solid dosage forms (tablets, powders, sponges, plate), and the rest - extracts and herbs. At the same time, 50% of the market - it's expensive imported medicines group B02BD - «Blood coagulation factors», which are inaccessible to most people.

Along with the medicines on the market there are medical devices to stop bleeding. This is a different gel dressings, bandages based on chitosan, zeolites, cellulose, powders based granular chitosan and zeolites such Celox, Combat, etc. However, according to Ukrainian legislation only etamsylate, which refers to a subgroup B02BX - «Other systemic hemostatic» is included in the range of medicines and medical devices for emergencies.

**Conclusions.** It is a marketing analysis of the Ukrainian market of hemostatic agents. It was found that only one drug - etamsylate included in the range of medicines and medical devices for emergencies, which is clearly insufficient.